How applicable is the single-dose AMBITION regimen for Human Immunodeficiency Virus–associated cryptococcal meningitis to high-income settings?. Harrison, T. S, Lawrence, D. S, Mwandumba, H. C, Boulware, D. R, Hosseinipour, M. C, Lortholary, O., Meintjes, G. A, Mosepele, M., & Jarvis, J. N Clinical Infectious Diseases, 76(5):944–949, mar, 2023. ![How applicable is the single-dose AMBITION regimen for Human Immunodeficiency Virus–associated cryptococcal meningitis to high-income settings? [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in eastern and southern Africa, showed that a single, high dose (10 mg/kg) of liposomal amphotericin B, given with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organization (WHO)–recommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency virus (HIV)–associated cryptococcal meningitis and has been incorporated into WHO treatment guidelines. We believe that the trial also has important implications for the treatment of HIV-associated cryptococcal meningitis in high-income settings. We advance the arguments, supported by evidence where available, that the AMBITION-cm trial regimen is likely to be as fungicidal as the currently recommended 14-day liposomal amphotericin–based treatments, better tolerated with fewer adverse effects, and confer significant economic and practical benefits and, therefore, should be included as a treatment option in guidance for HIV-associated cryptococcal treatment in high-income settings.
@article{Harrison2023,
abstract = {The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in eastern and southern Africa, showed that a single, high dose (10 mg/kg) of liposomal amphotericin B, given with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organization (WHO)–recommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency virus (HIV)–associated cryptococcal meningitis and has been incorporated into WHO treatment guidelines. We believe that the trial also has important implications for the treatment of HIV-associated cryptococcal meningitis in high-income settings. We advance the arguments, supported by evidence where available, that the AMBITION-cm trial regimen is likely to be as fungicidal as the currently recommended 14-day liposomal amphotericin–based treatments, better tolerated with fewer adverse effects, and confer significant economic and practical benefits and, therefore, should be included as a treatment option in guidance for HIV-associated cryptococcal treatment in high-income settings.},
author = {Harrison, Thomas S and Lawrence, David S and Mwandumba, Henry C and Boulware, David R and Hosseinipour, Mina C and Lortholary, Olivier and Meintjes, Graeme A and Mosepele, Mosepele and Jarvis, Joseph N},
doi = {10.1093/cid/ciac792},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Harrison et al. - 2023 - How applicable is the single-dose AMBITION regimen for Human Immunodeficiency Virus–associated cryptococcal men.pdf:pdf},
issn = {1058-4838},
journal = {Clinical Infectious Diseases},
keywords = {OA,OA{\_}PMC,fund{\_}not{\_}ack,original},
mendeley-tags = {OA,OA{\_}PMC,fund{\_}not{\_}ack,original},
month = {mar},
number = {5},
pages = {944--949},
pmid = {36166405},
title = {{How applicable is the single-dose AMBITION regimen for Human Immunodeficiency Virus–associated cryptococcal meningitis to high-income settings?}},
url = {https://doi.org/10.1093/cid/ciac792},
volume = {76},
year = {2023}
}
Downloads: 0
{"_id":"hh4aesEJ45hxNA3tj","bibbaseid":"harrison-lawrence-mwandumba-boulware-hosseinipour-lortholary-meintjes-mosepele-etal-howapplicableisthesingledoseambitionregimenforhumanimmunodeficiencyvirusassociatedcryptococcalmeningitistohighincomesettings-2023","author_short":["Harrison, T. S","Lawrence, D. S","Mwandumba, H. C","Boulware, D. R","Hosseinipour, M. C","Lortholary, O.","Meintjes, G. A","Mosepele, M.","Jarvis, J. N"],"bibdata":{"bibtype":"article","type":"article","abstract":"The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in eastern and southern Africa, showed that a single, high dose (10 mg/kg) of liposomal amphotericin B, given with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organization (WHO)–recommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency virus (HIV)–associated cryptococcal meningitis and has been incorporated into WHO treatment guidelines. We believe that the trial also has important implications for the treatment of HIV-associated cryptococcal meningitis in high-income settings. We advance the arguments, supported by evidence where available, that the AMBITION-cm trial regimen is likely to be as fungicidal as the currently recommended 14-day liposomal amphotericin–based treatments, better tolerated with fewer adverse effects, and confer significant economic and practical benefits and, therefore, should be included as a treatment option in guidance for HIV-associated cryptococcal treatment in high-income settings.","author":[{"propositions":[],"lastnames":["Harrison"],"firstnames":["Thomas","S"],"suffixes":[]},{"propositions":[],"lastnames":["Lawrence"],"firstnames":["David","S"],"suffixes":[]},{"propositions":[],"lastnames":["Mwandumba"],"firstnames":["Henry","C"],"suffixes":[]},{"propositions":[],"lastnames":["Boulware"],"firstnames":["David","R"],"suffixes":[]},{"propositions":[],"lastnames":["Hosseinipour"],"firstnames":["Mina","C"],"suffixes":[]},{"propositions":[],"lastnames":["Lortholary"],"firstnames":["Olivier"],"suffixes":[]},{"propositions":[],"lastnames":["Meintjes"],"firstnames":["Graeme","A"],"suffixes":[]},{"propositions":[],"lastnames":["Mosepele"],"firstnames":["Mosepele"],"suffixes":[]},{"propositions":[],"lastnames":["Jarvis"],"firstnames":["Joseph","N"],"suffixes":[]}],"doi":"10.1093/cid/ciac792","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Harrison et al. - 2023 - How applicable is the single-dose AMBITION regimen for Human Immunodeficiency Virus–associated cryptococcal men.pdf:pdf","issn":"1058-4838","journal":"Clinical Infectious Diseases","keywords":"OA,OA_PMC,fund_not_ack,original","mendeley-tags":"OA,OA_PMC,fund_not_ack,original","month":"mar","number":"5","pages":"944–949","pmid":"36166405","title":"How applicable is the single-dose AMBITION regimen for Human Immunodeficiency Virus–associated cryptococcal meningitis to high-income settings?","url":"https://doi.org/10.1093/cid/ciac792","volume":"76","year":"2023","bibtex":"@article{Harrison2023,\r\nabstract = {The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in eastern and southern Africa, showed that a single, high dose (10 mg/kg) of liposomal amphotericin B, given with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organization (WHO)–recommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency virus (HIV)–associated cryptococcal meningitis and has been incorporated into WHO treatment guidelines. We believe that the trial also has important implications for the treatment of HIV-associated cryptococcal meningitis in high-income settings. We advance the arguments, supported by evidence where available, that the AMBITION-cm trial regimen is likely to be as fungicidal as the currently recommended 14-day liposomal amphotericin–based treatments, better tolerated with fewer adverse effects, and confer significant economic and practical benefits and, therefore, should be included as a treatment option in guidance for HIV-associated cryptococcal treatment in high-income settings.},\r\nauthor = {Harrison, Thomas S and Lawrence, David S and Mwandumba, Henry C and Boulware, David R and Hosseinipour, Mina C and Lortholary, Olivier and Meintjes, Graeme A and Mosepele, Mosepele and Jarvis, Joseph N},\r\ndoi = {10.1093/cid/ciac792},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Harrison et al. - 2023 - How applicable is the single-dose AMBITION regimen for Human Immunodeficiency Virus–associated cryptococcal men.pdf:pdf},\r\nissn = {1058-4838},\r\njournal = {Clinical Infectious Diseases},\r\nkeywords = {OA,OA{\\_}PMC,fund{\\_}not{\\_}ack,original},\r\nmendeley-tags = {OA,OA{\\_}PMC,fund{\\_}not{\\_}ack,original},\r\nmonth = {mar},\r\nnumber = {5},\r\npages = {944--949},\r\npmid = {36166405},\r\ntitle = {{How applicable is the single-dose AMBITION regimen for Human Immunodeficiency Virus–associated cryptococcal meningitis to high-income settings?}},\r\nurl = {https://doi.org/10.1093/cid/ciac792},\r\nvolume = {76},\r\nyear = {2023}\r\n}\r\n","author_short":["Harrison, T. S","Lawrence, D. S","Mwandumba, H. C","Boulware, D. R","Hosseinipour, M. C","Lortholary, O.","Meintjes, G. A","Mosepele, M.","Jarvis, J. N"],"key":"Harrison2023","id":"Harrison2023","bibbaseid":"harrison-lawrence-mwandumba-boulware-hosseinipour-lortholary-meintjes-mosepele-etal-howapplicableisthesingledoseambitionregimenforhumanimmunodeficiencyvirusassociatedcryptococcalmeningitistohighincomesettings-2023","role":"author","urls":{"Paper":"https://doi.org/10.1093/cid/ciac792"},"keyword":["OA","OA_PMC","fund_not_ack","original"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh","KmoiX2LKn8hjsLMkh","XbBjMG3Fzj4C9dGTw"],"keywords":["oa","oa_pmc","fund_not_ack","original"],"search_terms":["applicable","single","dose","ambition","regimen","human","immunodeficiency","virus","associated","cryptococcal","meningitis","high","income","settings","harrison","lawrence","mwandumba","boulware","hosseinipour","lortholary","meintjes","mosepele","jarvis"],"title":"How applicable is the single-dose AMBITION regimen for Human Immunodeficiency Virus–associated cryptococcal meningitis to high-income settings?","year":2023}